{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": 2019
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 cause neurodegeneration by increasing kinase activity and toxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that LRRK2 mutations increase kinase activity, leading to neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Expression of LRRK2 G2019S in Drosophila models Parkinson's disease by promoting DA neurodegeneration.",
          "judgment": "Yes",
          "reasoning": "The assay used (Drosophila model) effectively models LRRK2-induced neurodegeneration."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: Wild-type LRRK2 and G2019S mutant were expressed in flies, and multiple replicates were used.\n\nStep 3c: Variant Controls: Known pathogenic variants (G2019S) were used as controls.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: Both wild-type and mutant controls were used, and experiments were performed in multiple replicates.\n\nStep 3c: Variant Controls: Pathogenic variants were used as positive controls."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Not evaluated",
          "judgment": "Not evaluated",
          "reasoning": "No information provided in the paper"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The LRRK2 G2019S variant shows significant pathogenicity in promoting DA neurodegeneration, supported by robust experimental design and statistical analyses."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": 1699
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 cause neurodegeneration by increasing kinase activity and toxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that LRRK2 mutations increase kinase activity, leading to neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Expression of LRRK2 Y1699C in Drosophila models Parkinson's disease by promoting DA neurodegeneration.",
          "judgment": "Yes",
          "reasoning": "The assay used (Drosophila model) effectively models LRRK2-induced neurodegeneration."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: Wild-type LRRK2 and Y1699C mutant were expressed in flies, and multiple replicates were used.\n\nStep 3c: Variant Controls: Known pathogenic variants (Y1699C) were used as controls.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: Both wild-type and mutant controls were used, and experiments were performed in multiple replicates.\n\nStep 3c: Variant Controls: Pathogenic variants were used as positive controls."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Not evaluated",
          "judgment": "Not evaluated",
          "reasoning": "No information provided in the paper"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The LRRK2 Y1699C variant shows pathogenicity in promoting DA neurodegeneration, but with less sensitivity to rotenone, indicating a different mechanism of neurodegeneration."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "R",
          "position": 2385
        },
        "variant_string_id": "LRRK2 G2385R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 cause neurodegeneration by increasing kinase activity and toxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that LRRK2 mutations increase kinase activity, leading to neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Expression of LRRK2 G2385R in Drosophila models Parkinson's disease by promoting DA neurodegeneration.",
          "judgment": "Yes",
          "reasoning": "The assay used (Drosophila model) effectively models LRRK2-induced neurodegeneration."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: Wild-type LRRK2 and G2385R mutant were expressed in flies, and multiple replicates were used.\n\nStep 3c: Variant Controls: Known pathogenic variants (G2385R) were used as controls.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: Both wild-type and mutant controls were used, and experiments were performed in multiple replicates.\n\nStep 3c: Variant Controls: Pathogenic variants were used as positive controls."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Not evaluated",
          "judgment": "Not evaluated",
          "reasoning": "No information provided in the paper"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The LRRK2 G2385R variant shows significant pathogenicity in promoting DA neurodegeneration, particularly in response to rotenone, supported by robust experimental design and statistical analyses."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": 2019
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 cause neurodegeneration by increasing kinase activity and toxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that LRRK2 mutations increase kinase activity, leading to neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Expression of LRRK2 G2019S in Drosophila models Parkinson's disease by promoting DA neurodegeneration.",
          "judgment": "Yes",
          "reasoning": "The assay used (Drosophila model) effectively models LRRK2-induced neurodegeneration."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: Wild-type LRRK2 and G2019S mutant were expressed in flies, and multiple replicates were used.\n\nStep 3c: Variant Controls: Known pathogenic variants (G2019S) were used as controls.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: Both wild-type and mutant controls were used, and experiments were performed in multiple replicates.\n\nStep 3c: Variant Controls: Pathogenic variants were used as positive controls."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Not evaluated",
          "judgment": "Not evaluated",
          "reasoning": "No information provided in the paper"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The LRRK2 G2019S variant shows significant pathogenicity in promoting DA neurodegeneration, supported by robust experimental design and statistical analyses."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": 1699
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 cause neurodegeneration by increasing kinase activity and toxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that LRRK2 mutations increase kinase activity, leading to neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Expression of LRRK2 Y1699C in Drosophila models Parkinson's disease by promoting DA neurodegeneration.",
          "judgment": "Yes",
          "reasoning": "The assay used (Drosophila model) effectively models LRRK2-induced neurodegeneration."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: Wild-type LRRK2 and Y1699C mutant were expressed in flies, and multiple replicates were used.\n\nStep 3c: Variant Controls: Known pathogenic variants (Y1699C) were used as controls.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: Both wild-type and mutant controls were used, and experiments were performed in multiple replicates.\n\nStep 3c: Variant Controls: Pathogenic variants were used as positive controls."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Not evaluated",
          "judgment": "Not evaluated",
          "reasoning": "No information provided in the paper"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The LRRK2 Y1699C variant shows pathogenicity in promoting DA neurodegeneration, but with less sensitivity to rotenone, indicating a different mechanism of neurodegeneration."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "R",
          "position": 2385
        },
        "variant_string_id": "LRRK2 G2385R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 cause neurodegeneration by increasing kinase activity and toxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that LRRK2 mutations increase kinase activity, leading to neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Expression of LRRK2 G2385R in Drosophila models Parkinson's disease by promoting DA neurodegeneration.",
          "judgment": "Yes",
          "reasoning": "The assay used (Drosophila model) effectively models LRRK2-induced neurodegeneration."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: Wild-type LRRK2 and G2385R mutant were expressed in flies, and multiple replicates were used.\n\nStep 3c: Variant Controls: Known pathogenic variants (G2385R) were used as controls.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: Both wild-type and mutant controls were used, and experiments were performed in multiple replicates.\n\nStep 3c: Variant Controls: Pathogenic variants were used as positive controls."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Not evaluated",
          "judgment": "Not evaluated",
          "reasoning": "No information provided in the paper"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The LRRK2 G2385R variant shows significant pathogenicity in promoting DA neurodegeneration, particularly in response to rotenone, supported by robust experimental design and statistical analyses."
    }
  ]
}